Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer
- Conditions
- Ovarian Cancer
- Registration Number
- NCT04752865
- Lead Sponsor
- Hellenic Cooperative Oncology Group
- Brief Summary
EFFECTS OF CYTOTOXIC CHEMOTHERAPY AND PARP INHIBITION ON THE GENOMIC CONTEXTURE OF OVARIAN CANCER: TR_NACT_OV/17 In order to approach the above open questions, ultimately aiming in understanding the effects of cancer drugs on tumor biology and hence in selecting the proper drugs for the patients in the context of Precision Medicine, the objective of this study is to study the genomic characteristics of ovarian tumors before and after treatment with classic neoadjuvant chemotherapy (NACT) and with the more recently approved PARP inhibitor olaparib.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
- ovarian cancer eligible for neoadjuvant chemotherapy
Exclusion Criteria
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method assesment of genomic characteristics of ovarian tumors at the diagnosis 4 years assesment of genomic characteristics of ovarian tumors after treatment with neoadjuvant platinum-based chemotherapy 4 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Adamantia Nikolaidi
🇬🇷Athens, Greece